ARCHIVES

Campath Improves PFS In B-Cell CLL In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 30 No. 1 | January 26, 2007

Download PDF Visit The Full Archive

Related Articles

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013

GAO Report Finds Hydrazine Sulfate Trials Were Accurate

September 29, 1995

In Brief: Construction Grant Transfer To USC Approved; Illinois Director Says NCI Pushed Consortia

January 20, 1978

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

April 9, 2010

NCI Raises R01 Payline To 16th Percentile FY09. Coalition Formed To Advocate For Medical Innovation

March 27, 2009

Funding Opportunities

March 7, 2003